Zaima Mazorra

1.8k total citations
32 papers, 1.2k citations indexed

About

Zaima Mazorra is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Zaima Mazorra has authored 32 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Immunology, 15 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Zaima Mazorra's work include Immunotherapy and Immune Responses (14 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Immune Cell Function and Interaction (9 papers). Zaima Mazorra is often cited by papers focused on Immunotherapy and Immune Responses (14 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Immune Cell Function and Interaction (9 papers). Zaima Mazorra collaborates with scholars based in Cuba, Switzerland and United States. Zaima Mazorra's co-authors include Lucia Mori, Gennaro De Libero, Tania Crombet, Abdijapar Shamshiev, Alena Donda, Luis E. Fernández, Sabrina Mariotti, Agustín Lage, Frederick Wittke and Jacques Prandi and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Zaima Mazorra

32 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zaima Mazorra Cuba 16 742 359 330 150 132 32 1.2k
Simona Buccheri Italy 16 796 1.1× 538 1.5× 545 1.7× 168 1.1× 96 0.7× 21 1.6k
George R. Gunn United States 11 547 0.7× 432 1.2× 475 1.4× 46 0.3× 379 2.9× 21 1.3k
Tala Shekarian Switzerland 11 694 0.9× 341 0.9× 675 2.0× 82 0.5× 59 0.4× 15 1.3k
Obinna Chijioke Switzerland 21 1.2k 1.6× 440 1.2× 898 2.7× 120 0.8× 55 0.4× 40 1.8k
Ernest Dodoo Sweden 15 335 0.5× 213 0.6× 314 1.0× 159 1.1× 44 0.3× 40 890
Raphaële Buser Switzerland 11 677 0.9× 262 0.7× 516 1.6× 124 0.8× 93 0.7× 11 1.2k
Courtney L. Erskine United States 15 558 0.8× 257 0.7× 478 1.4× 80 0.5× 117 0.9× 37 930
Dário Ligeiro Portugal 17 440 0.6× 371 1.0× 134 0.4× 68 0.5× 53 0.4× 47 895
Minlin Jiang China 12 453 0.6× 574 1.6× 410 1.2× 130 0.9× 59 0.4× 29 1.2k
Bruce A. Robbins United States 17 287 0.4× 192 0.5× 271 0.8× 44 0.3× 147 1.1× 26 963

Countries citing papers authored by Zaima Mazorra

Since Specialization
Citations

This map shows the geographic impact of Zaima Mazorra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zaima Mazorra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zaima Mazorra more than expected).

Fields of papers citing papers by Zaima Mazorra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zaima Mazorra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zaima Mazorra. The network helps show where Zaima Mazorra may publish in the future.

Co-authorship network of co-authors of Zaima Mazorra

This figure shows the co-authorship network connecting the top 25 collaborators of Zaima Mazorra. A scholar is included among the top collaborators of Zaima Mazorra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zaima Mazorra. Zaima Mazorra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Catalá, Mauricio, Patricia Lorenzo-Luaces, Raúl Ramos, et al.. (2022). Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Frontiers in Oncology. 12. 823287–823287. 5 indexed citations
2.
Figueredo, Carlos Marcelo, Mayra Ramos, Danay Saavedra, et al.. (2021). An Anti-CD6 Antibody for the Treatment of COVID-19 Patients with Cytokine-Release Syndrome: Report of Three Cases. Immunotherapy. 13(4). 289–295. 8 indexed citations
3.
Lorenzo-Luaces, Patricia, Elia Neninger, Mauricio Catalá, et al.. (2021). Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer. Cancer Immunology Immunotherapy. 70(6). 1735–1743. 8 indexed citations
4.
Ramos, Mayra, Danay Saavedra, Zaima Mazorra, et al.. (2020). Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19. Gerontology. 66(6). 553–561. 22 indexed citations
5.
Saavedra, Danay, Armando Caballero, Carmen Valenzuela, et al.. (2020). An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. Immunity & Ageing. 17(1). 34–34. 18 indexed citations
6.
Dy, Grace K., Marvin Reid, Kwanghyuk Lee, et al.. (2018). P2.04-26 Interim Results from a Phase I/II Trial of Nivolumab in Combination with CIMAvax-EGF as Second-Line Therapy in Advanced NSCLC. Journal of Thoracic Oncology. 13(10). S740–S740. 2 indexed citations
7.
Saavedra, Danay, Elia Neninger, Carmen Viada, et al.. (2018). CIMAvax-EGF: Toward long-term survival of advanced NSCLC. Seminars in Oncology. 45(1-2). 34–40. 17 indexed citations
8.
Mazorra, Zaima, et al.. (2018). Nimotuzumab: beyond the EGFR signaling cascade inhibition. Seminars in Oncology. 45(1-2). 18–26. 51 indexed citations
9.
Mazorra, Zaima, Fernando Concha‐Benavente, Raghvendra M. Srivastava, et al.. (2017). Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. Frontiers in Pharmacology. 8. 382–382. 44 indexed citations
10.
Macías, Amparo, et al.. (2016). P2.34: Vaxira and CIMAvax-EGF Therapeutic Vaccines Combination in the Advanced NSCLC Treatment. Journal of Thoracic Oncology. 11(10). S236–S237. 1 indexed citations
11.
Hernández, Patricia, et al.. (2015). Immunological evaluation of rheumatoid arthritis patients treated with itolizumab. mAbs. 8(1). 187–195. 15 indexed citations
12.
López‐Requena, Alejandro, et al.. (2014). Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab. mAbs. 6(3). 782–792. 25 indexed citations
13.
Crombet, Tania, Elia Neninger, Pedro C. Rodríguez, et al.. (2013). EGF-based cancer vaccine: Optimizing predictive and surrogate biomarkers.. Journal of Clinical Oncology. 31(15_suppl). 3013–3013. 6 indexed citations
14.
Mulens‐Arias, Vladimir, Ana de la Torre, Patricia Marinello, et al.. (2010). Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients.. Human Vaccines. 6(9). 736–744. 36 indexed citations
15.
Mazorra, Zaima, et al.. (2009). GM3 ganglioside: a novel target for the therapy against melanoma. SHILAP Revista de lepidopterología. 26(3). 256–259. 4 indexed citations
16.
Mazorra, Zaima, Circe Mesa, Audry Fernández, & Luis E. Fernández. (2008). Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8+ T cells-mediated protection against melanoma B16 challenge. Cancer Immunology Immunotherapy. 57(12). 1771–1780. 9 indexed citations
17.
Neninger, Elia, Beatriz García Verdecia, Tania Crombet, et al.. (2008). Combining an EGF-based Cancer Vaccine With Chemotherapy in Advanced Nonsmall Cell Lung Cancer. Journal of Immunotherapy. 32(1). 92–99. 53 indexed citations
18.
Libero, Gennaro De, Anthony P. Moran, Emmanuel Rossy, et al.. (2005). Bacterial Infections Promote T Cell Recognition of Self-Glycolipids. Immunity. 22(6). 763–772. 89 indexed citations
19.
Carr, Adriana, Zaima Mazorra, Daniel F. Alonso, et al.. (2001). A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo. Melanoma Research. 11(3). 219–227. 28 indexed citations
20.
Carr, Adriana, Zaima Mazorra, Ana María Vázquez, et al.. (2000). A Mouse IgG 1 Monoclonal Antibody Specific for N -Glycolyl GM3 Ganglioside Recognized Breast and Melanoma Tumors. Hybridoma. 19(3). 241–247. 105 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Simona Buccheri Breakdown of academic impact, for papers by George R. Gunn Breakdown of academic impact, for papers by Tala Shekarian Breakdown of academic impact, for papers by Obinna Chijioke Breakdown of academic impact, for papers by Ernest Dodoo Breakdown of academic impact, for papers by Raphaële Buser Breakdown of academic impact, for papers by Courtney L. Erskine Breakdown of academic impact, for papers by Dário Ligeiro Breakdown of academic impact, for papers by Minlin Jiang Breakdown of academic impact, for papers by Bruce A. Robbins
Rankless by CCL
2026